| Bioactivity | D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro[1]. | |||||||||
| Invitro | D-erythro-MAPP (D-e-MAPP) reduces the viability of MCF-7 cells in a dose-dependent manner with IC50 value of 4.4 μM, and 15.6 μM, respectively[1].D-erythro-MAPP (D-e-MAPP) induces G0/G1 arrest in cell cycle progression resulting in growth suppression[2]. Cell Viability Assay[1] Cell Line: | |||||||||
| Name | D-erythro-MAPP | |||||||||
| CAS | 143492-38-0 | |||||||||
| Formula | C23H39NO2 | |||||||||
| Molar Mass | 361.56 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Hüseyin İzgördü, et al. Characteristics of apoptosis induction in human breast cancer cells treated with a ceramidase inhibitor. Cytotechnology. 2020 Dec;72(6):907-919. [2]. A Bielawska, et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem. 1996 May 24;271(21):12646-54. |